What is the appropriate fludrocortisone dosage for a patient with Addison's disease who has persistent tachycardia?

Fludrocortisone Dosage in Addison's Disease with Tachycardia

In an Addison's patient with tachycardia, reduce the fludrocortisone dose to 0.05 mg daily and reassess, as tachycardia likely indicates mineralocorticoid excess rather than deficiency. 1, 2

Clinical Approach to Tachycardia in This Context

Tachycardia in an Addison's patient on replacement therapy suggests over-replacement with fludrocortisone rather than under-replacement, as mineralocorticoid excess causes volume overload and cardiovascular strain 2, 3. The key is distinguishing between mineralocorticoid excess and other causes:

Signs of Fludrocortisone Over-Replacement to Assess:

• Peripheral edema 4
• Hypertension (supine and standing blood pressure should be measured) 4
• Hypokalemia (low potassium is a sensitive marker of excess) 5, 6
• Suppressed plasma renin activity 6
• Absence of salt cravings or orthostatic symptoms 4

Recommended Dosing Strategy:

If signs of mineralocorticoid excess are present:

• Reduce fludrocortisone to 0.05 mg daily 1, 3
• The FDA label specifically recommends this dose reduction when transient hypertension or cardiovascular symptoms develop 1
• A case report documented severe cardiovascular complications (Takotsubo-like cardiomyopathy with tachycardia) from fludrocortisone overdose at 0.3 mg daily, which resolved after reduction to 0.05 mg daily 3

Standard fludrocortisone dosing range:

• 50-200 µg (0.05-0.2 mg) daily is the typical range for most adults with primary adrenal insufficiency 4, 1
• The usual starting dose is 0.1 mg daily 1
• Higher doses up to 500 µg may be needed in children, younger adults, or during late pregnancy 4

Important Caveats:

Before attributing tachycardia solely to fludrocortisone excess, verify:

• Glucocorticoid replacement is not excessive - over-replacement with hydrocortisone can cause insomnia, weight gain, and edema, which may contribute to cardiovascular symptoms 4
• Glucocorticoid replacement is adequate - under-replacement can be compensated by mineralocorticoid over-replacement, creating a vicious cycle 4
• The patient is not taking interacting medications that potentiate mineralocorticoid effects (liquorice, carbenoxolone, NSAIDs) 4

Monitoring Parameters After Dose Adjustment:

• Serum sodium and potassium (potassium normalization indicates appropriate dosing) 6
• Plasma renin activity (should be in mid-normal range; suppressed renin suggests excess, elevated renin suggests deficiency) 6
• Blood pressure (supine and standing) 4
• Clinical symptoms (resolution of tachycardia, absence of salt cravings, no orthostatic lightheadedness) 4

A recent 6-year cohort study demonstrated that fludrocortisone doses can often be reduced during long-term follow-up, and that renin and electrolytes reliably indicate mineralocorticoid activity 6. This supports the strategy of dose reduction when cardiovascular symptoms like tachycardia emerge.

Critical Pitfall to Avoid:

Never stop fludrocortisone entirely even if hypertension or tachycardia develops - mineralocorticoids are vital for blood pressure and electrolyte homeostasis 4. Instead, reduce the dose and consider adding a vasodilator if essential hypertension persists after dose optimization 4.